Canadian International Pharma Corp. Proceeds with Agreement to Sell Generic and OTC Products in Canada
2489 Bellevue Avenue, West Vancouver, BC Canada V7V 1E1 . Tel 604.922.2030 . Fax 604.922.2037
News Release No: 17-06
Trading symbol: TSX-V - NEX: CIP.H
Canadian International Pharma Corp. Proceeds with Agreement
to Sell Generic and OTC Products in Canada
West Vancouver, British Columbia, November 20, 2017 – Canadian International Pharma Corp.
(the “Company” or “CIPC”) – In 2016, CIPC entered into an agency agreement (the “Agreement”) with a
Canadian based pharmaceutical company that discovers, develops, manufactures and markets a broad
range of healthcare products (the “Manufacturer”), to sell and market a number of generic and over the
counter (“OTC”) medications (the “Products”) in Canada, and in connection therewith, the Manufacturer
has recently obtained required approvals for selling certain of its Products in Canada.
The Agreement permits CIPC to generate sales of the Products in the Provinces of British Columbia,
Alberta and Saskatchewan, with additional territories under review . Initially, CIPC will be marketing a
variety of the Products, including such generic medications as Anastrozole (breast cancer treatment),
Citalopram (depression), Letrozole (breast cancer) , Ondansetron (nausea from cancer treatment) ,
Rizatriptan Odt (migraine) and Zolmitriptan (migraine), as well as certain over the counter products ,
such as Bisacodyl (laxative), Comfilax (herbal product for digestion and constipation) and Hot Lemon
Relief (cold and flu relief). Additionally, the Company has the potential opportunity of marketing other
products as the Manufacturer receives DIN registrations for such medications.
In light of the above developments, the Company will be actively presenting the Products to a number
of chain and independent pharmacies located in British Columbia, Alberta and Saskatchewan in an
effort to obtain 2018 product placements and listings for such Products.
About Canadian International Pharma Corp.
CIPC is an emerging multi-faceted pharmaceutical company that is in the process of developing generic
and nutraceutical drug manufacturing, distribution and sales. In 2016, CIPC launched its PharmaCert
Program. PharmaCert is a certification program for testin g and measuring finished dosage forms of
nutraceutical and pharmaceutical medications. The Company is continuing to pursue alliances with
Canadian and US manufacturers with the objective of manufacturing generics and nutraceuticals for
Canadian and overseas markets.
For further information, contact Mr. Clive Shallow, Shareholder Communications, at 604-922-2030, or visit
the Company’s website at www.canpharmacorp.ca.
CANADIAN INTERNATIONAL PHARMA CORP.
“Mehrun Payravi”
____________________________________________
Mehrun Payravi, President
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of TSX Venture
Exchange) accepts responsibility for the adequacy of accuracy of this release.
FORWARD-LOOKING STATEMENTS
This release includes certain statements that may be deemed “forward-looking statements” within the meaning of applicable
securities legislation . All statements, other than historical facts, are forward -looking statements and are genera lly, but not
2489 Bellevue Avenue, West Vancouver, BC Canada V7V 1E1 . Tel 604.922.2030 . Fax 604.922.2037
always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “suspects”, “intends”, “estimates”, “projects”,
”targets”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “sho uld” occur. The
Company’s statements regarding business opportunities from the sale of pharmaceutical and over the counter medications
and products and from its PharmaCert Program, its cross licencing business, the engagement of its business development
agents and attendances at upcoming conference and trade shows are forward-looking statements and although the Company
believes the expectations expressed in such forward -looking statements are based on reasonable assumptions, such
statements are not guarante es of future performance and actual results may differ mate rially from those expressed in, or
implied by, this forward-looking information. Factors that could cause actual results to differ materially from those in forward -
looking statements include such matters as market prices for the Company’s anticipated products, regulatory approvals
required for the Company’s business plans, continued availability of capital and financing, and general economic, market or
business conditions. Any forward -looking statements are expressly qualified in their entirety by this cautionary statement.
Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date such
statements were made. The Company expressly disclaims any intention or obligation to update or revise any forward -looking
statements whether as a result of new information, future events or otherwise.
This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities des cribed herein in the
United States. The securities described herein have not been and will not be registered under the United States Securities Act
of 1933, as amended, and may not be offered or sold in the United States or to the account or benefit of a U.S. person absent
an exemption from the registration requirements of such Act.